Drug Profile
NMI 300
Alternative Names: NMI-300Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Nemucore Medical Innovations
- Class Antineoplastics; Gadolinium-containing contrast agents; Platinum complexes; Small molecules; Sphingolipids
- Mechanism of Action Diagnostic imaging enhancers; DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Ovarian-cancer(Diagnosis) in USA (Parenteral)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Ovarian-cancer(Treatment-resistant) in USA (Parenteral)
- 23 Feb 2016 Phase-I clinical trials in Ovarian cancer (Diagnosis) in USA (Parenteral), before January 2016